View in EDS HTML Full Text PDF Full Text

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.

Saved in:
Bibliographic Details
Title: Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.
Authors: Zhang Y; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Wang W; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Li Q; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Ye L; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Zhou X; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Jiang L; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Ma L; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Luo Y; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China., Tong H; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.
Source: Blood cancer journal [Blood Cancer J] 2026 May 29; Vol. 16 (1). Date of Electronic Publication: 2026 May 29.
Publication Type: Letter
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42215444
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Wang+W%22">Wang W</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Li+Q%22">Li Q</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Ye+L%22">Ye L</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Zhou+X%22">Zhou X</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Jiang+L%22">Jiang L</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Ma+L%22">Ma L</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Luo+Y%22">Luo Y</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China.<br /><searchLink fieldCode="AU" term="%22Tong+H%22">Tong H</searchLink>; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.; Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.; Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, China. tonghongyan@zju.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2026 May 29; Vol. 16 (1). <i>Date of Electronic Publication: </i>2026 May 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42215444
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-026-01529-4
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Wang W
      – PersonEntity:
          Name:
            NameFull: Li Q
      – PersonEntity:
          Name:
            NameFull: Ye L
      – PersonEntity:
          Name:
            NameFull: Zhou X
      – PersonEntity:
          Name:
            NameFull: Jiang L
      – PersonEntity:
          Name:
            NameFull: Ma L
      – PersonEntity:
          Name:
            NameFull: Luo Y
      – PersonEntity:
          Name:
            NameFull: Tong H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 05
              Text: 2026 May 29
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1